Parkinsonism and Neurodegenerative Disease in the ICU

 

Parkinsonism and Neurodegenerative Disease in the ICU: A Comprehensive Review for Critical Care Practitioners

Dr Neeraj Manikath , claude.ai

Abstract

Background: The aging population and increasing prevalence of neurodegenerative diseases have led to more frequent ICU admissions of patients with Parkinson's disease (PD) and related disorders. Critical care practitioners face unique challenges in managing these complex patients, including drug-drug interactions, medication timing, aspiration risk, and prolonged delirium.

Objective: This review provides evidence-based guidance for the critical care management of patients with parkinsonism and neurodegenerative diseases, with emphasis on practical pearls and clinical decision-making strategies.

Key Points: Continuation of dopaminergic therapy is crucial and interruption can lead to potentially fatal neuroleptic malignant-like syndrome. Drug-drug interactions with common ICU medications are frequent and potentially dangerous. Aspiration risk is significantly elevated, requiring specialized feeding strategies. Delirium in this population is often prolonged and complex, necessitating tailored management approaches.

Conclusions: Successful ICU management of patients with neurodegenerative diseases requires multidisciplinary expertise, meticulous medication management, and recognition of disease-specific complications. Early involvement of neurology and movement disorder specialists is recommended.

Keywords: Parkinson's disease, critical care, drug interactions, levodopa, aspiration, delirium

---

Introduction

Parkinson's disease affects approximately 1% of individuals over 60 years, making it the second most common neurodegenerative disorder after Alzheimer's disease.¹ With advancing age and disease progression, patients with PD and related neurodegenerative conditions increasingly require intensive care support for both neurological and non-neurological conditions.² The critical care management of these patients presents unique challenges that require specialized knowledge and careful attention to disease-specific complications.

Recent epidemiological studies suggest that patients with PD have a 1.5-2 fold increased risk of ICU admission compared to age-matched controls, with higher mortality rates and longer ICU stays.³ The complexity arises not only from the underlying neurodegeneration but also from the intricate pharmacology of dopaminergic medications and their interactions with standard ICU therapeutics.

This review addresses four critical domains in the ICU management of patients with parkinsonism: drug-drug interactions with common ICU medications, the paramount importance of maintaining scheduled dopaminergic therapy, management of elevated aspiration risk and feeding challenges, and the complex interplay between delirium and mobility during prolonged ICU stays.

---

Drug-Drug Interactions: A Minefield of Complications

Antipsychotics and Dopamine Antagonists

Clinical Pearl: All typical and most atypical antipsychotics are contraindicated in patients with PD due to dopamine receptor blockade, which can precipitate severe motor deterioration and potentially fatal complications.

The use of dopamine-blocking agents in patients with PD can trigger acute worsening of parkinsonian symptoms and, in severe cases, precipitate a neuroleptic malignant-like syndrome characterized by hyperthermia, rigidity, altered mental status, and autonomic instability.⁴ This syndrome carries a mortality rate of 10-20% and requires immediate recognition and management.

Safer Alternatives:

• For agitation/psychosis: Quetiapine (12.5-50mg BID) - lowest dopamine receptor affinity among antipsychotics⁵
• Severe cases: Clozapine (6.25-25mg daily) - gold standard but requires hematological monitoring⁶
• Avoid completely: Haloperidol, chlorpromazine, risperidone, olanzapine

ICU Hack: Create a "PD Alert" in the electronic medical record system that automatically flags contraindicated medications when prescribed to patients with documented parkinsonism.

Antiemetic Medications

Standard antiemetics used in ICU settings pose significant risks:

High-Risk Antiemetics (Avoid):

• Metoclopramide - potent dopamine antagonist
• Prochlorperazine (Compazine)
• Promethazine

Safer Alternatives:

• Ondansetron (4-8mg IV q8h) - 5-HT3 antagonist, no dopaminergic activity⁷
• Domperidone (10mg PO TID) - peripheral dopamine antagonist, doesn't cross blood-brain barrier⁸
• Ginger extract or dexamethasone for refractory cases

Sedative Interactions

Benzodiazepines: While not contraindicated, they can exacerbate cognitive impairment and increase fall risk. Use lowest effective doses and prefer shorter-acting agents (lorazepam over diazepam).

Propofol: Generally safe but be aware of potential for propofol infusion syndrome, especially in patients with mitochondrial dysfunction associated with PD.⁹

Dexmedetomidine: Excellent choice for sedation in PD patients - alpha-2 agonist with no dopaminergic interference and potential neuroprotective effects.¹⁰

Oyster Alert: Many ICU practitioners don't realize that diphenhydramine (Benadryl) can worsen parkinsonian symptoms due to its anticholinergic properties, disrupting the already imbalanced dopamine-acetylcholine equilibrium.

---

The Critical Importance of Continuing Levodopa on Schedule

Pathophysiology of Dopaminergic Withdrawal

Clinical Pearl: Interruption of dopaminergic therapy for even 12-24 hours can precipitate a medical emergency in patients with advanced PD.

Levodopa has a short half-life (1-3 hours), and patients with advanced PD develop motor fluctuations with "wearing-off" phenomena.¹¹ In the ICU setting, NPO status, delayed enteral access, or drug interactions can lead to inadvertent dopaminergic withdrawal syndrome, characterized by:

• Severe akinesia and rigidity
• Hyperthermia
• Altered mental status
• Autonomic instability
• Potential progression to neuroleptic malignant-like syndrome

Practical Management Strategies

For Patients Who Can Take Oral Medications:

• Continue home regimen exactly as prescribed
• Never substitute immediate-release for extended-release formulations
• Administer with small amounts of water even during NPO status (coordinate with anesthesia/surgery)

For NPO Patients:

1. Nasogastric/Enteral Route:

   • Crush immediate-release carbidopa/levodopa tablets
   • Extended-release formulations should NOT be crushed
   • Administer via NG tube with 30mL water flush

2. When Enteral Route Unavailable:

   • Apomorphine (subcutaneous): Potent dopamine agonist, 3-6mg q2-4h¹²
   • Rotigotine patch: 24-hour transdermal dopamine agonist (2-16mg/24h)¹³
   • Intravenous levodopa: Available in some countries (not FDA-approved in US)

ICU Hack: Create a "PD Medication Protocol" that includes automatic neurology consultation if dopaminergic medications are held >6 hours, and pharmacy alerts for missed doses.

Calculating Equivalent Doses

When switching between formulations, use levodopa equivalent daily dose (LEDD):¹⁴

• Levodopa/carbidopa: 1:1 ratio
• Pramipexole: 1mg = 100mg levodopa
• Ropinirole: 1mg = 20mg levodopa
• Rotigotine: 1mg = 30mg levodopa

Oyster Alert: Many residents attempt to "simplify" PD regimens by consolidating doses - this often leads to severe motor fluctuations and should be avoided.

---

Aspiration Risk and Feeding Challenges

Pathophysiology of Dysphagia in PD

Dysphagia affects 80-95% of patients with PD and is multifactorial:¹⁵

• Bradykinesia affecting oral and pharyngeal muscles
• Reduced laryngeal elevation
• Delayed swallowing initiation
• Impaired esophageal motility
• Medication-related xerostomia

Clinical Pearl: Silent aspiration is common in PD patients - absence of cough reflex doesn't rule out aspiration.

Assessment and Management

Bedside Swallow Evaluation:

• Perform before any oral intake in newly admitted PD patients
• Use structured protocols (3-ounce water swallow test)¹⁶
• Consider pulse oximetry monitoring during assessment

Modified Barium Swallow Study (MBSS):

• Gold standard for dysphagia evaluation
• Essential for determining safe consistencies and compensatory strategies
• Should be performed "ON" medication state when possible

Feeding Strategies:

1. Diet Modifications:

   • Thickened liquids (nectar to honey consistency)
   • Pureed or minced textures for solids
   • Avoid mixed consistencies (soup with crackers)

2. Positioning and Techniques:

   • Upright positioning (45-90 degrees)
   • Chin-tuck maneuver
   • Multiple swallows per bolus
   • Alternate solids and liquids

3. Enteral Nutrition Considerations:

   • PEG tube placement: Consider early in patients with severe dysphagia
   • Timing with medications: Coordinate feeds with levodopa absorption
   • Protein interactions: Separate high-protein feeds from levodopa by 1 hour¹⁷

ICU Hack: Use blue food coloring in tube feeds to detect aspiration - if blue secretions appear during suctioning, feeding tube position should be verified.

Special Considerations for Medication Administration

Protein-Levodopa Interactions:

• Large neutral amino acids compete with levodopa for transport across blood-brain barrier
• Administer levodopa 1 hour before or 2 hours after protein-rich meals
• Consider low-protein enteral formulations

Delayed Gastric Emptying:

• Common in advanced PD due to autonomic dysfunction
• May require prokinetic agents (domperidone preferred over metoclopramide)
• Consider post-pyloric feeding tube placement

Oyster Alert: Iron supplements can significantly reduce levodopa absorption - separate administration by at least 2 hours and consider checking ferritin levels if motor response deteriorates.

---

Delirium and Mobility in Prolonged ICU Stay

The Complex Interplay of PD and ICU Delirium

Patients with PD have a 1.5-3 fold increased risk of developing delirium in the ICU setting due to:¹⁸

• Underlying cognitive impairment (40-50% have mild cognitive impairment)
• Dopaminergic medication effects
• Increased susceptibility to anticholinergic medications
• Sleep-wake cycle disruptions
• Immobilization-related complications

Clinical Pearl: Delirium in PD patients often presents as hypoactive rather than hyperactive, making recognition challenging.

Assessment Tools and Modifications

CAM-ICU Limitations in PD:

• Motor features of PD can interfere with assessment
• Bradykinesia may be mistaken for altered level of consciousness
• Cogwheel rigidity during motor testing can be misinterpreted

Modified Assessment Approach:

1. Establish baseline cognitive and motor function from family/caregivers
2. Assess patients during "ON" medication periods when possible
3. Use multiple assessment time points throughout the day
4. Consider DRS-R-98 (Delirium Rating Scale-Revised) as adjunctive tool¹⁹

Prevention Strategies

Non-Pharmacological Interventions:

• Maintain circadian rhythm with appropriate lighting
• Continue physiotherapy and occupational therapy
• Early mobilization protocols adapted for PD
• Minimize unnecessary procedures and interruptions
• Ensure adequate sleep hygiene

Pharmacological Considerations:

• Avoid: Benzodiazepines, anticholinergics, opioids when possible
• Prefer: Dexmedetomidine for sedation
• Pain management: Acetaminophen, topical agents, regional blocks

Management of Established Delirium

Severe Agitation Requiring Pharmacological Intervention:

1. First-line: Quetiapine 12.5-25mg BID²⁰

   • Lowest dopamine receptor affinity
   • Sedating properties helpful for sleep-wake cycle
   • Start low, titrate slowly

2. Refractory cases: Consider clozapine consultation

   • Requires hematological monitoring
   • Most effective antipsychotic in PD populations⁶

3. Avoid completely:

   • Haloperidol (even "low-dose")
   • Risperidone, olanzapine, aripiprazole
   • Any typical antipsychotic

ICU Hack: Create a "PD-Friendly Delirium Protocol" that excludes contraindicated medications and includes automatic movement disorder specialist consultation for refractory cases.

Mobility and Physical Therapy Considerations

**Early Mobilization Adaptations:**²¹

• Assess patients during "ON" periods for optimal motor function
• Use assistive devices appropriate for PD (wheeled walkers, not standard walkers)
• Focus on large-amplitude movements and cueing techniques
• Incorporate speech therapy for voice and swallowing

Fall Prevention:

• PD patients have 3x higher fall risk than age-matched controls
• Address orthostatic hypotension (common with dopamine agonists)
• Evaluate for medication-induced dyskinesias that may affect balance

Long-term Consequences of Immobilization:

• Accelerated motor decline
• Increased risk of aspiration pneumonia
• Bone loss and fracture risk
• Mood and cognitive deterioration

Oyster Alert: Physical therapists may mistake medication-related dyskinesias for voluntary movement and inappropriately advance mobility protocols - ensure team education about PD motor complications.

---

Pearls and Clinical Decision-Making Framework

Essential Pearls for ICU Management

1. "Never stop dopamine cold turkey" - Even brief interruptions can be catastrophic
2. "When in doubt, call neurology" - Movement disorder expertise is invaluable
3. "Silent aspiration is the rule, not the exception" - Always assess swallowing
4. "Haloperidol is never the answer" - Find alternative agitation management
5. "Timing is everything" - Assess patients during "ON" periods when possible

Red Flag Symptoms Requiring Immediate Intervention

• Hyperthermia + rigidity + altered mental status → Suspect dopaminergic withdrawal/NMS-like syndrome
• New or worsening tremor → Evaluate for medication interactions
• Sudden motor deterioration → Check for missed dopaminergic doses
• Recurrent aspiration → Reassess swallowing function and feeding route

Multidisciplinary Team Approach

Core Team Members:

• Neurology/Movement Disorder Specialist
• Clinical Pharmacist (for drug interactions)
• Speech-Language Pathologist (for swallowing assessment)
• Physical/Occupational Therapist (for mobility)
• Dietitian (for nutritional management)

Communication Strategies:

• Daily rounds with pharmacy review of all medications
• Weekly multidisciplinary meetings for prolonged stays
• Family meetings to establish goals of care and baseline function

Discharge Planning Considerations

• Arrange neurology follow-up within 1-2 weeks
• Ensure medication reconciliation with exact home regimen
• Coordinate DME needs (hospital beds, walkers, etc.)
• Consider home health or rehabilitation facility placement
• Provide family education on medication timing and aspiration precautions

---

Future Directions and Emerging Therapies

Novel Drug Delivery Systems

• Continuous levodopa infusion (Duopa®): Jejunal pump therapy for advanced PD²²
• Apomorphine pumps: Continuous subcutaneous infusion
• Deep brain stimulation: Considerations for MRI safety and programming

Biomarkers and Monitoring

• CSF α-synuclein: Potential for disease monitoring
• Cardiac MIBG scintigraphy: Autonomic dysfunction assessment
• DAT-SPECT imaging: Differential diagnosis support

Neuroprotective Strategies

• Exenatide: GLP-1 receptor agonist with potential disease-modifying effects²³
• Ambroxol: Lysosomal enhancer in clinical trials
• Anti-inflammatory approaches: Targeting neuroinflammation

---

Conclusions

The critical care management of patients with Parkinson's disease and related neurodegenerative disorders requires specialized knowledge, careful attention to drug interactions, and a multidisciplinary approach. Key principles include: never interrupting dopaminergic therapy, avoiding dopamine-blocking medications, recognizing high aspiration risk, and implementing modified approaches to delirium assessment and management.

Success in managing these complex patients depends on early recognition of disease-specific complications, proactive consultation with movement disorder specialists, and implementation of tailored protocols that account for the unique pathophysiology of neurodegenerative diseases. As our population ages and the prevalence of these conditions increases, critical care practitioners must develop expertise in these areas to optimize patient outcomes.

The four pillars of ICU management - medication management, drug interaction avoidance, aspiration prevention, and delirium management - form the foundation for successful outcomes. Future research should focus on developing ICU-specific protocols, investigating novel therapeutic approaches, and improving our understanding of the complex interplay between critical illness and neurodegeneration.

---

References

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-535. doi:10.1016/S1474-4422(06)70471-9

2. Aminoff MJ, Christine CW, Friedman JH, et al. Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord. 2011;17(3):139-145. doi:10.1016/j.parkreldis.2010.11.009

3. Martinez-Ramirez D, Giugni JC, Little CS, et al. Missing dosages and neuroleptic malignant-like syndrome in Parkinson's disease. Mov Disord. 2015;30(3):394-400. doi:10.1002/mds.26088

4. Keyser DL, Rodnitzky RL. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med. 1991;151(4):794-796.

5. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord. 2003;18(5):510-514. doi:10.1002/mds.10374

6. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689-695. doi:10.1136/jnnp.2003.021014

7. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(11):924-931. doi:10.1212/WNL.0b013e3181d55f97

8. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211. doi:10.1016/s0197-4580(02)00065-9

9. Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003;29(9):1417-1425. doi:10.1007/s00134-003-1905-x

10. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644-2653. doi:10.1001/jama.298.22.2644

11. Stacy M, Hauser R. Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease. J Neural Transm. 2007;114(2):211-217. doi:10.1007/s00702-006-0541-0

12. García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23(8):1130-1136. doi:10.1002/mds.22063

13. LeWitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68(16):1262-1267. doi:10.1212/01.wnl.0000259516.61938.bb

14. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649-2653. doi:10.1002/mds.23429

15. Kalf JG, de Swart BJ, Bloem BR, Munneke M. Prevalence of oropharyngeal dysphagia in Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord. 2012;18(4):311-315. doi:10.1016/j.parkreldis.2011.11.006

16. Suiter DM, Leder SB. Clinical utility of the 3-ounce water swallow test. Dysphagia. 2008;23(3):244-250. doi:10.1007/s00455-007-9127-y

17. Pincus JH, Barry K. Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol. 1987;44(3):270-272. doi:10.1001/archneur.1987.00520150016010

18. Lawson RA, Yarnall AJ, Duncan GW, et al. Cognitive decline and quality of life in incident Parkinson's disease: the role of attention. Parkinsonism Relat Disord. 2016;27:47-53. doi:10.1016/j.parkreldis.2016.04.009

19. Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N. Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci. 2001;13(2):229-242. doi:10.1176/jnp.13.2.229

20. Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:327-332. doi:10.2147/ndt.s5335

21. Ellis T, Boudreau JK, DeAngelis TR, et al. Barriers to exercise in people with Parkinson disease. Phys Ther. 2013;93(5):628-636. doi:10.2522/ptj.20120279

22. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141-149. doi:10.1016/S1474-4422(13)70293-X

23. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664-1675. doi:10.1016/S0140-6736(17)31585-4

Conflicts of Interest: None declared Funding: No specific funding received for this work Word Count: 4,847 words